Search

Displaying results 4061 - 4070 of 10000 in total
  1. Drug

    Smilagenin

    go.drugbank.com/drugs/DB05450
    Investigational

    in Parkinson’s disease. … P58 is a protein synthesis stimulant acts by restoring levels of proteins that are altered in the ageing brain, reversing the loss of nerve receptors in the ageing brain and potentially allowing for the

  2. Drug

    TAS-108

    go.drugbank.com/drugs/DB05966
    Investigational

  3. Drug

    Dilazep

    go.drugbank.com/drugs/DB13715
    Experimental

    Categories: Vasodilators Used in Cardiac Diseases
  4. Drug

    Zirconium dioxide

    go.drugbank.com/drugs/DB16552
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Glyceraldehyde-3-Phosphate Dehydrogenase

    go.drugbank.com/drugs/DB17012
    Experimental

    Categories: Oxidoreductases Acting on Aldehyde or Oxo Group Donors
  6. Drug

    Maltotetraose

    go.drugbank.com/drugs/DB02237
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Mitoquinone

    go.drugbank.com/drugs/DB05063
    Investigational

    Mitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease. … In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease.

  8. Drug

    Malacidin B

    go.drugbank.com/drugs/DB14052
    Experimental

    Malacidin B, along with [DB14051], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312].

  9. Drug

    Malacidin A

    go.drugbank.com/drugs/DB14051
    Experimental

    Malacidin A, along with [DB14052], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312].

  10. Drug

    Lefamulin

    go.drugbank.com/drugs/DB12825
    Approved

    [A183206] Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.